Value of biomarkers in osteoarthritis: current status and perspectives

被引：223

作者：

Lotz, M. ^{[1
]}

Martel-Pelletier, J. ^{[2
]}

Christiansen, C. ^{[3
]}

Brandi, M-L ^{[4
]}

Bruyere, O. ^{[5
]}

Chapurlat, R. ^{[6
,7
]}

Collette, J. ^{[8
]}

Cooper, C. ^{[9
,10
]}

Giacovelli, G. ^{[11
]}

Kanis, J. A. ^{[12
]}

Karsdal, M. A. ^{[3
]}

Kraus, V. ^{[13
]}

Lems, W. F. ^{[14
]}

Meulenbelt, I. ^{[15
]}

Pelletier, J-P ^{[2
]}

Raynauld, J-P ^{[2
]}

Reiter-Niesert, S. ^{[16
]}

Rizzoli, R. ^{[17
,18
]}

Sandell, L. J. ^{[19
]}

Van Spil, W. E. ^{[20
]}

Reginster, J-Y ^{[21
,22
]}

机构：

[1] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA

[2] Univ Montreal Hosp Res Ctr CRCHUM, Osteoarthrit Res Unit, Montreal, PQ, Canada

[3] Nord Biosci AS, Herlev, Denmark

[4] Univ Florence, Dept Internal Med, Bone Metab Unit, Florence, Italy

[5] Univ Liege, Dept Publ Hlth Epidemiol & Hlth Econ, Liege, Belgium

[6] INSERM, UMR 1033, F-69008 Lyon, France

[7] Univ Lyon, Hop Edouard Herriot, Serv Rhumatol & Pathol Osseuse, Lyon, France

[8] Univ Liege, CHU, Bone & Cartilage Markers Lab, Dept Clin Chem, Liege, Belgium

[9] Univ Southampton, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England

[10] Univ Oxford, NIHR Musculoskeletal Biomed Res Unit, Oxford, England

[11] Rottapharm Madaus Grp, Clin Res Unit, Monza, Italy

[12] Univ Sheffield, Sch Med, WHO Collaborating Ctr Metab Bone Dis, Sheffield, S Yorkshire, England

[13] Duke Univ, Sch Med, Dept Med, Div Rheumatol, Durham, NC 27706 USA

[14] Vrije Univ Amsterdam Med Ctr, Dept Rheumatol, Amsterdam, Netherlands

[15] Leiden Univ Med Ctr, Sect Mol Epidemiol, Leiden, Netherlands

[16] Fed Inst Drugs & Med Devices BfArM, Bonn, Germany

[17] Univ Hosp Geneva, Div Bone Dis, Geneva, Switzerland

[18] Fac Med, Geneva, Switzerland

[19] Washington Univ, Dept Cell Biol & Physiol, St Louis, MO USA

[20] Univ Med Ctr Utrecht, Dept Rheumatol & Clin Immunol, Utrecht, Netherlands

[21] Univ Liege, Bone & Cartilage Metab Res Unit, Liege, Belgium

[22] Univ Liege, Dept Publ Hlth Sci, CHU Ctr Ville, Policlin L Brull, Liege, Belgium

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 72卷 / 11期

关键词：

Osteoarthritis; Outcomes research; Inflammation; SYNOVIAL-FLUID LEVELS; C-REACTIVE PROTEIN; BIOCHEMICAL MARKERS; KNEE OSTEOARTHRITIS; RADIOGRAPHIC OSTEOARTHRITIS; RHEUMATOID-ARTHRITIS; CTX-II; BIOLOGICAL MARKERS; AGGRECAN FRAGMENTS; PROTEOMIC ANALYSIS;

D O I：

10.1136/annrheumdis-2013-203726

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Osteoarthritis affects the whole joint structure with progressive changes in cartilage, menisci, ligaments and subchondral bone, and synovial inflammation. Biomarkers are being developed to quantify joint remodelling and disease progression. This article was prepared following a working meeting of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis convened to discuss the value of biochemical markers of matrix metabolism in drug development in osteoarthritis. The best candidates are generally molecules or molecular fragments present in cartilage, bone or synovium and may be specific to one type of joint tissue or common to them all. Many currently investigated biomarkers are associated with collagen metabolism in cartilage or bone, or aggrecan metabolism in cartilage. Other biomarkers are related to non-collagenous proteins, inflammation and/or fibrosis. Biomarkers in osteoarthritis can be categorised using the burden of disease, investigative, prognostic, efficacy of intervention, diagnostic and safety classification. There are a number of promising candidates, notably urinary C-terminal telopeptide of collagen type II and serum cartilage oligomeric protein, although none is sufficiently discriminating to differentiate between individual patients and controls (diagnostic) or between patients with different disease severities (burden of disease), predict prognosis in individuals with or without osteoarthritis (prognostic) or perform so consistently that it could function as a surrogate outcome in clinical trials (efficacy of intervention). Future avenues for research include exploration of underlying mechanisms of disease and development of new biomarkers; technological development; the omics' (genomics, metabolomics, proteomics and lipidomics); design of aggregate scores combining a panel of biomarkers and/or imaging markers into single diagnostic algorithms; and investigation into the relationship between biomarkers and prognosis.

引用

页码：1756 / 1763

页数：8

共 86 条

[1] Global metabolic profiling of human osteoarthritic synovium
Adams, S. B., Jr.
Setton, L. A.
Kensicki, E.
Bolognesi, M. P.
Toth, A. P.
Nettles, D. L.
[J]. OSTEOARTHRITIS AND CARTILAGE, 2012, 20 (01) : 64 - 67
[2] [Anonymous], 2010, GUID CLIN INV MED PR
[3] Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
Atkinson, AJ
Colburn, WA
DeGruttola, VG
DeMets, DL
Downing, GJ
Hoth, DF
Oates, JA
Peck, CC
Schooley, RT
Spilker, BA
Woodcock, J
Zeger, SL
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) : 89 - 95
[4] Classification of osteoarthritis biomarkers:: a proposed approach
Bauer, D. C.
Hunter, D. J.
Abramson, S. B.
Attur, M.
Corr, M.
Felson, D.
Heinegard, D.
Jordan, J. M.
Kepler, T. B.
Lane, N. E.
Saxne, T.
Tyree, B.
Kraus, V. B.
[J]. OSTEOARTHRITIS AND CARTILAGE, 2006, 14 (08) : 723 - 727
[5] Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM-Increased serum CIIM in subjects with severe radiographic osteoarthritis
Bay-Jensen, Anne-Christine
Liu, Qi
Byrjalsen, Inger
Li, Yi
Wang, Jianxia
Pedersen, Christian
Leeming, Diana J.
Dam, Erik B.
Zheng, Qinlong
Qvist, Per
Karsdal, Morten A.
[J]. CLINICAL BIOCHEMISTRY, 2011, 44 (5-6) : 423 - 429
[6] Adiponectin and its receptors are expressed in bone-forming cells
Berner, HS
Lyngstadaas, SP
Spahr, A
Monjo, M
Thommesen, L
Drevon, CA
Syversen, U
Reseland, JE
[J]. BONE, 2004, 35 (04) : 842 - 849
[7] Temporal Relationship Between Serum Adipokines, Biomarkers of Bone and Cartilage Turnover, and Cartilage Volume Loss in a Population With Clinical Knee Osteoarthritis
Berry, Patricia A.
Jones, Simon W.
Cicuttini, Flavia M.
Wluka, Anita
Maciewicz, Rose A.
[J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (03): : 700 - 707
[8] Relationship of serum markers of cartilage metabolism to imaging and clinical outcome measures of knee joint structure
Berry, Patricia A.
Maciewicz, Rose A.
Wluka, Anita
Downey-Jones, Mark D.
Forbes, Andrew
Hellawell, Caroline J.
Cicuttini, Flavia M.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (10) : 1816 - 1822
[9] Osteoarthritis: an update with relevance for clinical practice
Bijlsma, Johannes W. J.
Berenbaum, Francis
Lafeber, Foris P. J. G.
[J]. LANCET, 2011, 377 (9783) : 2115 - 2126
[10] Metabolic health in families enriched for longevity is associated with low prevalence of hand osteoarthritis and influences OA biomarker profiles
Bos, Steffan Daniel
Beekman, Marian
Maier, Andrea B.
Karsdal, Morton A.
Kwok, Wing-Yee
Bay-Jensen, Anne Christine
Kloppenburg, Margreet
Slagboom, P. Eline
Meulenbelt, Ingrid
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (10) : 1669 - 1674

← 1 2 3 4 5 6 7 8 9 →